Transplantation of bone marrow from SCID mice into lethally irradiated normal mice can potentially endow the normal recipients with characteristics typical of the immunedeficient SClD mouse. In the present study, we invedgated whether intra(Mritonea1 grafting of human peripheral blood lymphocytes (PBLs), which has been documented in the SCID mouse, can also be achieved in irradiated BALBIc mice radioprotected with SCID bone marrow. Evaluation of different radiation protocols suggested that, considering the quality of engraftment and rate of survival, optimal results were obtained with sprit dose total body irradiation (TBI; 4 Gy followed 3 days later by 10 Gy). Monitoring of mouse T cells in peripheral blood indicated an inverse correlation between the presence of such cells and the engraftment of human CD&+ cells in the peritoneum. Also, engraftment of human PBLs in nude BALBIc mice, conditioned with the same radiation protocol, was significantly higher than that achieved in their normal counterparts. Further improvement of human PBL engraftment was found when the mice were thymectomized 2 weeks before conditioning with split TBI. After transplantation of 80 x lo6 human PBLs in such recipients, a marked engraftment of human T cells and B cells in the peritoneum cavity could be detected for at least 2 months, whereas significant amounts of human Ig could be detected for more than 3 months. Migration of human PBLs into internal organs such as spleen, liver, kidney, and lungs (and into thymus in nonthymectomized mice) was found within a few days of grafting and also persisted for 2 to 3 months. The majority of the engrafted lymphocytes were single-positive CD4+ and CD8' T lymphocytes, about 50% of which were activated, as judged by their expression of HLA-DR. Staining with anti-CD25 antibody was lower compared with that HE FEASIBILITY OF transplantation of human peripheral blood lymphocytes (PBLs)' into the SCID mouse? which has been introduced during the past few has opened up new possibilities in human immunology, virology, and cancer research (for review see Mosier"). In particular, it has been shown that engrafted human lymphocytes can produce antibodies to a recall antigen4.6.9.'6,'9-21 and that they can be infected with human immunodeficiency virus
they would still possess natural antibodies that can interfere with engraftment of hematopoiesis? 1 Nevertheless, Lubin et aI3* have shown that this goal can be achieved in lethally irradiated mice if the recipients are radioprotected with SCID bone marrow and then transplanted with a large dose of human bone marrow, but the generation of human T cells after such transplants was very slow and was mainly of the CD3TD4-CD8-phenotype. Also, human Ig levels were very low (<l00 pg/mL). More recently, immunohistochemical analysis of the residual thymus did not show evidence for human T-cell differentiation (unpublished results) and it was therefore reasonable to assume that the emergence of human cells after a transplantation of human bone marrow was the result of some lymphocyte proliferation rather than maturation. This conclusion led to the present investigation, in which we used PBLs, instead of bone marrow, as the source of human hematopoietic tissue in lethally irradiated mice radioprotected with SCID bone marrow. We tested different conditioning protocols and found that, despite the presence of natural antibodies in BALB/c and other normal strains of mice, a combination of thymectomy and split radiation afforded rapid engraftment and prompt distribution of the major human lymphocyte subpopulations in different organs for prolonged periods of time.
MATERIALS AND METHODS
Mice. Animals used were 6 to 10 weeks old. BALBlc mice were obtained from Olac Farms (Bicester, UK), outbred immune deficient beige/nude/Xid (BNX) mice from Harlan Sprague Dawley (Indianapolis, IN), CBNJ and C3wHeJ mice from Roscoe B. Jackson Memorial Laboratory (Bar Harbor, ME), nude BALB/c mice from Memorial Sloan Kettering Cancer Center (New York, NY), and SCID mice from the Weizmann Institute Animal Breeding Center (Rehovot, Israel). A breeding pair of C57BU6-HLA class I (B7) transgenic mice were kindly provided by Dr Uli Hammerling from the Memorial Sloan Kettering Cancer Center and a colony was established at the Weizmann Institute Animal Breeding Center. All mice were kept in small cages (5 animals in each cage) and fed sterile food and acid water containing cyprofloxacin (20 pg/mL).
Conditioning regimen. BALB/c mice were exposed to total body irradiation (TBI) from a gamma beam 150-A "CO source (produced by the Atomic Energy of Canada, Kanata, Ontario, Canada) with focal skin distance of 75 cm and a dose rate of 0.7 Gy/min, either with 10 Gy (single dose) or with 4 Gy followed 3 days later by 10 Gy (split dose). Some of the mice were thyme~tomized~~ 2 weeks before exposure to split irradiation. Other strains of mice were irradiated as described in the Results.
Preparation and transplantation of T-cell-depleted bone marrow cells. Bone marrow cells obtained from SCID mice (4 to 10 weeks old) were fractionated by differential agglutination with soybean agglutinin (to remove T lymphocytes that may be present in occasional "leaky" SCID mice) according to Reisner et al-with minor modification^?^ Recipient mice were injected with 2 to 3 X lo6 Tcell-depleted SCID bone marrow cells (intravenously [Iv] in 0.2 mL phosphate-buffered saline [PBS]) 1 day after irradiation.
Preparation and transplantation of human PBLs. Buffy coats from normal volunteers were layered onto Lymphoprep solution (Nycomed, Oslo, Norway) and spun at 2,000 rpm for 20 minutes. The interlayer was collected, washed twice, counted, and resuspended in PBS, pH 7.4 , to the desired cell concentration. Various numbers of human PBLS were injected intraperitoneally (IP) into recipient mice, conditioned as described above. Control mice did not receive human PBLS.
Cell and plasma collection from human + mouse chimera. Animals were bled from the retro-orbital vein using heparin-coated glass capillaries. PBLs were isolated using Lymphoprep, washed with PBS containing 1% bovine serum albumin (BSA), and stained for fluorescence-activated cell sorter (FACS) analysis. Plasma was kept for human-Ig determination. Peritoneal cells were obtained by lavage with 2 to 4 mL PBS. Organs were removed after the animals were killed by cervical dislocation. The organs were cut into pieces and pressed through stainless steel sieves to make a cell suspension in PBS, and cells were then isolated using Lymphoprep.
FACS analysis. Single-cell suspensions were incubated for 30 minutes on ice with a mixture of appropriate fluorescently labeled monoclonal antibodies. After washing, double-or three-color fluorescent analysis of human antigens was performed on a FACScan analyser (Becton Dickinson, Mountain View, CA). The labeled antibodies used recognize specific surface molecules: CD45-fluorescein isothiocyanate (FITC) (pan leukocyte antigen); CD3-peridinin chlorophyll protein (PerCP) (pan-T cells); CD14-phycoerythrin (PE) (pan monocytes); CD20-PE (pan-B cells); CD25-FITC (interleukin-2 [IL-21 receptor); CD4-PE (T-helper cells); CD8-FITC (T-cytotoxic cells); HLA-DR-PE CD45RA-FITC (naive cells); L3T4-PE (antimouse CD4); and Lyt2-FITC (antimouse CD8). All the above antibodies were purchased from Becton Dickinson. CD45RO-PE (memory cells) was purchased from Serotec (Oxford, UK). Anti-CD45 conjugated to Tri-color (TC; Cy-5 coupled to R-phycoerythrin) was purchased from Catlag Laboratories (San Francisco, CA). For staining of lymphocytes from human + C3H chimeras, the cells were first incubated with a11ti-H-2~ antibodies specific for the SCID donor origin (20-8-45 , a gift from D. Sachs) or with anti-H-2' specific for host-type origin (H-100-5R28, a gift from G. Hammerling, Memorial Sloan Kettering Cancer Center, New York, NY) and were then stained with goat antimouse IgG2A antibody conjugated to FITC (Nordic Immunological Laboratories, Tilburg, The Netherlands), anti-L3T4-PE, and anti-CD3-PerCP.
Human Ig determination. Human Ig was quantified by sandwich enzyme-linked immunosorbent assay (ELISA) using goat F(ab),-purified antihuman Ig (Zymed Laboratories, San Francisco, CA) as the capture agent and peroxidase-conjugated purified goat antihuman Ig (Zymed Laboratories) as the detection reagent. Human serum of known Ig concentration was used as the standard. Microplates (Nunc, Roskilde, Denmark) precoated with the capture reagent (5 &mL, 50 pUwell) and blocked with 1% BSA were incubated overnight at 4°C with dilutions of plasma from 1/500 to 1/16,000, or the standard from 1 to 0.05 &mL, and then washed three times with PBS-Tween solution. The detection reagent was added and the plates were incubated for 2 hours at 37°C and then washed again three times. Fresh substrate solution was added and, after peroxidase-catalyzed color development, the absorbance at 405 nm was quantified on an ELISA reader (Dynatech, Port Guernsey, Channel Islands, UK).
Outgrowth of human B-cell lines from human + mouse chimera by Epstein-Barr virus (EBV) transformation. BALB/c mice were treated by thymectomy and split TBI, transplanted IV with 2.5 x lo6 T-cell-depleted SCID bone marrow cells, followed by IP infusion of 50 X lo6 human PBLs. Thirty days posttransplant, cells were recovered from different organs, purified on Lymphoprep gradient, incubated with 1 mL EBV (€395-8 substrain) for 1 hour, washed, and incubated with 20 Gy irradiated feeder cells (human PBLs) in medium supplemented with 0.5 pg/mL cyclosporin A. Human Ig concentration was determined in supernatants derived from culture with a density of 0.5 to 1.0 X lo6 proliferating cells/mL.
RESULTS
In accordance with the study of Lubin et a1; * we began our study in BALB/c mice by using conditioning with 10. Days post-transplant Gy TB1 and radioprotection with SCID bone marrow cells. Because Mosier et all reported that in the SCID mouse the intraperitoneal route was advantageous for human PBL engraftment and because Lubin et a13' could not find engraftment of human PBLs after IV infusion, we repeated our earlier experiments with human PBLs by transplanting these cells IP. Initial engraftment was attained, but it was limited to 45% of mice and lasted for less than 3 weeks, similar to what is generally found in allogeneic transplantation when the conditioning of the recipient is not optimal. Therefore, the basic conditioning was intensified after evaluating the contribution of different chemotherapy and irradiation modalities, which had previously been shown to be important in the allogeneic mouse model. For monitoring the engraftment while optimizing the protocols, we chose to use doublestaining with anti-CD3 and anti-CD45 antibodies, and we also assessed the human Ig levels in the serum. The latter was found to be a more sensitive indicator for the presence of human PBLs in the SCID model! Split-dose TBZ. Cudkowicz and Bennett36 have shown that an initial low dose of irradiation followed a few days later by a lethal dose effectively abrogates hybrid or allogeneic resistance in mice, without adding to the associated mortality. We therefore attempted to condition BALB/c mice with split-dose irradiation. Optimal results were attained when 4 Gy was administered 3 days before the second dose of TBI. Doses higher than 4 Gy, or administration of the second dose 1 or 2 days after the initial dose, led to higher mortality. Administration of the second dose 4 to 10 days after the initial dose resulted in a significantly lower rate of engraftment (data not shown). During the first month posttransplant, both the magnitude and the incidence of engraftment were markedly enhanced by the optimal split radiation (Fig 1) ; engraftment of more than 10% CD45+ human cells was found in 73 of 94 mice (average engraftment in positive mice was 43.8% ? 2.7% CD45' cells). PBLs that were poorly engrafted (less than 10% CD45' cells in more than half the mice in each experiment) seemed to be associated with particular donors (data not shown). During the second month, engraftment of more than 10% CD45+ human cells was found in 11 of 73 mice.
Role of mouse T cells in rejection of human PBLs. Immediately after a single-dose irradiation (10 to 10.5 Gy TBI), the number of residual murine T cells is extremely low. However, in a large proportion of the mice, we found an increase in the number of such cells towards the end of the first month posttransplant. A detailed study (Lubin et al, unpublished results), using SCID (H-2d) bone marrow for radioprotection of C3H (H-2k) mice, showed that the majority of the newly formed T cells originate in the thymus from residual C3H precursors and not from leaky SCID stem cells. Therefore, we looked for a correlation in individual mice between the engraftment of human PBLs and the level of residual T cells. Because the major subpopulation of T cells is represented by the CD4+ cells, we routinely stained PBLs from individual mice with anti-UT4 (anti-CD4) mouse antibody. A typical triple staining with antimouse CD4, antihuman CD3, and antihuman CD45, in an engrafted mouse and in a nonengrafted mouse, is shown in Fig 2. The successfully engrafted mouse shows the presence of CD45+ cells and hardly any mouse CD4' cells, whereas a high level of mouse CD4+ cells is detected in the mouse that had no engraftment, and thus no CD45+ cells. The pooled data (Fig 3) radiation show a significant (P = .0001) inverse correlation between the presence of murine CD4' cells in blood and CD4.5' peritoneal cells, strongly indicating that the regenerating mouse T cells in lethally irradiated mice may be capable of resisting engraftment of human PBLs.
The rationale for using SCID bone marrow for radiopro- tection before transplantation of human PBLs is largely based on the assumption that transplanted SCID stem cells cannot give rise to T or B cells, which could potentially reject human xenografts. We tested this assumption by comparing the engraftment of human PBLs in BALB/c mice radioprotected either with SCID bone marrow or with normal T-cell-depleted BALB/c bone marrow. As can be seen in 0017 by Student's t-test). As expected, the mice engrafted with human lymphocytes had low levels of murine CD4+ T cells, whereas recipients of BALB/c bone marrow, which uniformly rejected the human xenograft, displayed high levels of mouse CD4+ T cells.
The possible role of residual mouse T cells was further substantiated by an experiment in which engraftment of human PBLs from specific donors was shown to be significantly more successful in BALB/c nude recipients compared with normal BALB/c mice (Fig S) . For example, the average engraftment of CD3' in the nude mice was 44.7% 2 11.8%, whereas in the normal BALB/c mice this value was 16.2% t 5.3% (P < .OS by Student's t-test). Significant differences were also found in the engraftment of CD4' and CD8' human T cells (Fig 9 , as well as CD3-CD45' lymphocytes (data not shown). The engraftment of CD20+ human B lymphocytes was low, as expected from their frequency in PBLs, and the difference between the nude and the normal group was not significant (P = .14). Also, as expected, the freFor personal use only. on October 26, 2017. by guest www.bloodjournal.org From quency of mouse CD4+ T cells in the nude mice was very low and a marked difference was found between the two groups (0.6% ? 0.2% v 20.2% ? 5.6%; P < .003).
Effect of cell dose. The optimization of the conditioning protocols was performed mainly by using an inoculum of 40 X lo6 PBLs per mouse. Clearly, however, the transplanted lymphocytes may also have an effect on the resistance of the recipients if the graft is able to mount a response against the recipient lymphocytes. To investigate this possibility, and to optimize the cell dose used for transplantation, we compared the engraftment of CD3+CD45+ human T lymphocytes versus the frequency of CD4 mouse lymphocytes after transplantation of different cell doses in recipients conditioned by split TBI. In the entire study we used lymphocytes from the same donor because we had already found a marked variability in the engraftment of human PBLs from different donors. As can be seen in Table 1 cells was about sixfold greater than that obtained after transplantation of 10 X IO6 cells. Engrafhnent of human PBLs is enhanced in thymectomized mice. Our finding that the nude recipient allows better engraftment of human PBLs and that the negative correlation in individual mice between the appearance of mouse CD4+ T cells and engraftment of human CD45+ cells, led us to hypothesize that the presence of host type residual T cells, which are generated in the thymus a few weeks after the transplant, may interfere with the engraftment of human PBLs. Therefore, preventing the development of such cells by thymectomy may enhance engraftment of the human cells. As can be seen in Fig 6, thymectomy 2 weeks before the conditioning and transplantation procedure was advantageous and led to improved engraftment of human PBLs. In particular, the effect was significant when analyzed during the second month posttransplant, at which time engraftment in nonthymectomized mice conditioned with split radiation was reduced in correlation with the appearance of mouse T cells in the peripheral blood. Average percentages of peritoneal human CD45' cells during the second month posttransplant (including mice receiving PBIs from the particular donors associated with poor initial engraftment) in thymectomized and nonthymectomized mice were 14.6 ? 2.4 and 5.3 5 1.6, respectively (P = .012). Analysis by the Student's ttest showed a significant reduction (P = .0001) in the frequency of murine CD4+ cells in thymectomized mice during the second month posttransplant compared with nonthymectomized mice treated with the same split radiation protocol (results not shown).
Organ distribution of human lymphocyte subpopulations at different intervals after transplantation. For the evaluation of organ distribution of human lymphocytes after transplantation, we also chose to test (at different intervals) mice that were transplanted with lymphocytes from the same donor. Thymectomized BALB/c mice were exposed to split TB1 (4 Gy 3 days before 10 Gy), radioprotected with SCID bone marrow cells, and then transplanted with 80 X lo6 human PBLs. At different intervals after transplantation, mice were killed and the lymphocytes in various organs were phenotyped by different monoclonal antibodies. Typical staining, pairing different antihuman antibodies (against the antigens CD45, CD3, CD4, CD8, CD14, CD20, CD25 HLA-DR, CD45RO and CD45RA), is shown in Fig 7. A summary of the data demonstrating the presence of CD45' cells, CD3+ cells, and CD20' cells in different organs of individual mice at different time intervals after transplantation is shown in Fig 8. As early as 1 day after transplantation, human lymphocytes were found not only in the peritoneum (85%) but also in the liver (26%), lungs (6%), and spleen (39%). In nonthymectomized mice, C D 4 9 lymphocytes were also found in the thymus (22.39% 2 13.12% CD45; data not shown). Lymph nodes were almost nonexistent and therefore the presence of human lymphocytes in these sites was difficult to evaluate. The percentage of human CD45' cells in the peritoneum, as well as in the internal organs, markedly decreased by day 20 to less than 10% and thereaf- ter began to increase, reaching maximal levels (32% in the peripheral blood and more than 60% in spleen, liver, and lung) on day 36. This high level has sharply decreased in the peritoneum and in the peripheral blood by day 42; but in the lung, liver, and spleen it continued to be greater than 15% up to day 51. Total numbers of human C D 4 F cells, based on absolute cell count in the different organs, were tested in some experiments, and showed a similar pattern to that reflected by the percentages of positive cells. The total CD45+ cells recovered from internal organs reached a maximum between the third and fourth week posttransplant (average, 28 ? 13 X lo6; range, 0.4 to 39.8 X lo6 CD45+ cells).
Cell distribution between peritoneum, spleen, and other internal organs, 1 month posttransplant, was 9.2 ? 6 X lo6, 3 .3 2 2.3 X lo6, and 15.1 2 7.5 X lo6, respectively. By the end of the second month posttransplant, the average total number of CD45+ cells declined sharply to less than 1 X lo6 cells. However, up to the last time point on day 112, human CD45+ cells could still be detected (range, 0.1% to 31%). Throughout this follow-up, the human CD45+ cells were largely composed of CD4+ and CD8+ T cells (Fig 7) , as well as human B cells (CD20+, Figs 7 and 8) . Doublestaining with antihuman CD3 and antihuman HLA-DR, 42 days posttransplant, shows that about 50% of the human T cells in the mouse organs are activated (Fig 7) . However, most of the HLA-DR+ cells exhibited low or negative staining with anti-CD25 More than 90% of the T cells have the phenotype of memory cells, as shown by double-staining with anti-CD45RO and anti-CD45RA. Human B cells, although found in smaller numbers than T cells (as can be expected from their low incidence in PBLs), seem to home preferably to the spleen, but they are also found in other organs. Human CD14+ monocytes were detected in the peritoneum only a few days posttransplant, and were not detected thereafter.
Total human Ig in engrafted mice. Titers of human Ig
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were routinely tested in sera of transplanted BALB/c mice by ELISA. On the whole, we found that this assay was the most sensitive for detecting the presence of engrafted human lymphocytes. Thus, even in mice that showed very low frequency of human lymphocytes in the peritoneum wash, we often found significant titers of human Ig (data not shown), presumably caused by the homing of antibody-producing cells to the spleen and to other internal organs (Fig 8) . A high level of human Ig in transplanted mice was attained as early as day 14 (average of 2.8 mg/mL) and continued at this level for 4 more weeks, declining thereafter to an average of 1.2 mg/mL at 2 months, and to about 0.3 mg/mL at 3 months posttransplant (Fig 9) .
In vitro EBV transformation of human B cells recovered from the human -+ mouse chimera. Because the human + mice chimera could be used to generate lymphocytes, from which human monoclonal antibody-producing cell lines against different antigens can be established, it was of interest to evaluate the feasibility of immortalizing human B cells from different organs of the chimeric mice. Cells recovered 4 weeks after transplantation were infected in vitro with EBV. In the cells of 2 of 3 mice, we successfully established EBV-immortalized cultures from the spleen (secreting 0.8 and 4.2 pg/mL human Ig), liver (0.6 and 0.7 pg/mL human Ig), and blood (2.8 pg/mL human Ig). Most of the cultures were of p and y isotypes. Staining of living cells with rabbit antihuman Igs showed that, of these 5 cultures, 2 were predominantly positive for IgM, 2 for IgG, and 1 was weakly stained for IgA. K and A surface positive cells were found in each of these polyclonal cell lines. No cultures developed from peritoneum and lung cells of the 3 mice, but EBVimmortalized cultures were established from peritoneum cells from 2 other mice (secreting 2.0 and 1.0 pg/mL human Ig). All cell cultures were EBV-nuclear antigen (EBNA) positive.
Survival of human + mouse chimera. The transplanted mice in our study were routinely manipulated by repeated bleeding or by intraperitoneal washing. Even with this treatment, overall survival was in the range of 40% to 70%, similar to that generally found after bone marrow transplantation in mice. Mice with hair loss and skin lesions were that on day 62 they were from the spleen.
occasionally observed, but no correlation could be found with engraftment of human PBLs in these mice compared with other mice that did not show such manifestations. In most instances, the hair loss and skin lesions were resolved after a few weeks. Significant mortality (25% of 98 transplanted mice) occurred during the first 20 days posttransplant, reaching 40% to 50% mortality on day 100 posttransplant, and thereafter was limited to an occasional death. Similar mortality was found in a control group of 38 mice, which were conditioned by split T B 1 and were radioprotected by a bone marrow transplant from SCID donors without an additional transplant of human PBLs. The overall survival in both groups was almost identical (no significant difference by the Mantel-Cox test, P = .61). Also, no significant difference was found when the survival in these two groups was compared with that of the group of 152 mice conditioned with split TB1 after thymectomy (P = .l1 and P = .09, respectively), suggesting that the role of xenoreactivity or graft-versus-host disease (GVHD) was minimal. Unlike the results in the SCID m~d e l , ' *~~.~' we did not find EBV lymphomas in the BALB/c recipients, even though we used a larger cell dose and a great number of randomly selected blood donors.
Other strains of mice. In the experiments described above, engraftment of human PBLs in BALB/c mice was performed after transplantation of SCID bone marrow, which is H-2 identical with the BALB/c recipients. To ascertain whether our approach can be widely used to achieve engraftment of human cells in different strains of mice, we also tested other recipients, such as C3H/HeJ and CBNJ mice, or the HLA class I (B7) C57BW6 transgenic mice, as well as the immunodeficient outbred BNX mice, all of which are H-2 noncompatible with the SCID bone marrow donors. The transgenic recipients, which are more radioresistant than the BALB/c mice (because of their C57BU6 background), were subjected to the split-radiation protocol, except that the second dose was increased to 12 Gy TBI. Evaluation of human PBL engraftment, by testing total human Ig in the serum 20 days after transplant, showed levels similar to those obtained in BAL.B/c recipients ( was achieved after conditioning with split TB1 (4 Gy followed by 11 Gy). Typical double-staining of human CD45 versus CD3, as well as of mouse H-2 (H-2d or H-2') versus mouse CD4 in an engrafted mouse and in a nonengrafted mouse (Fig lo) , shows that murine CD4+ T cells can hardly be detected in the engrafted mouse, whereas a significant number of such cells are found in the mouse rejecting the transplant, and are exclusively of host-type (H-2') and not of SCID origin (H-2d). The BNX mice were initially tested by using a low TB1 dose (4 Gy), as described by Kamel-Reid and Dick3* for the engraftment of human hematopoietic progenitors, but engraftment was extremely limited (Fig 11A) . Marked improvement of engraftment was found after conditioning with a lethal dose of 12 Gy TB1 and radioprotection with SCID bone marrow (Fig 11A) . Tests of Ig levels in the serum of individual mice were performed during a 6-month followup period, although repeated bleeding led to an increase in mortality after 3 months posttransplant. Consistent high titers ( 2 mg/mL) were obtained during 5 months (Fig 11B) , decreasing to l mg/mL at 6 months posttransplant. In contrast to the human -+ BALB/c chimera, lymphomas were found in about 20% of the BNX recipients of human PBLs. The survival of the human -+ BNX chimera during the first 3 months posttransplant was comparable to that found in the human -+ BALB/c chimera, suggesting that lethally irradiated BNX recipients of human PBLs could also be useful for eliciting human antibody responses, as a step towards the production of human cell lines that engender monoclonal antibodies.
DISCUSSION
In the present study, we demonstrate the feasibility of a general approach to engraft human PBLs in normal strains of mice. Our approach is based on supralethal conditioning of the recipient mice, to eradicate most of their normal hematopoietic system, followed by radioprotection with a transplant of bone marrow from an SCID donor, which promptly reconstitutes the entire hematopoietic system except for the lymphoid lineage. In this way, we were able to convert a normal hematopoietic system into an SCID-like system. Optimal results were obtained by conditioning thymectomized BALB/c mice with split (4 Gy + 10 Gy) TBI, followed by radioprotection with 2 to 3 X lo6 T-cell-depleted SCID bone marrow and transplantation of 80 X lo6 human PBLs.
T-cell subpopulations, as well as B cells, were successfully engrafted in significant numbers and were found in different internal organs for at least 2 months. Human Ig production at an average titer of 2.8 mg/mL was achieved within 14 days posttransplant and remained significant for more than 3 months. Furthermore, we showed that cells derived from various organs of the chimera can be immortalized in vitro with EBV into human lymphoblastoid cell lines. Most of the human B cells were found in internal organs (such as spleen, liver, and lung) and a very small number was recorded in the peripheral blood. Nevertheless, the EBV transformation technique enabled outgrowth of B-cell lines secreting human Ig even from the blood. Thus, it may be possible to establish cell lines to produce human monoclonal antibody from immunized chimeric mice without sacrificing them.
The target cells of EBV are Ig surface positive and EBVreceptor positive. Plasma cells and blasts cannot be immortalized by the virus. The fact that we immortalized resting p and y surface positive B cells indicates that, among the after TB1 and radioprotection with SCID bone marrow, some immortalized lymphocytes, there were at least some that mortality always occurs due to the associated severe aplasia. were not virgin lymphocytes. The differentiation of B cells Thereafter, occasional deaths were caused by infections, in the chimera is, no doubt, a dynamic process, and the which were probably aggravated by repeated blood testing, timing of cell recovery for EBV immortalization must, therebut could also be complicated by the xenoreactivity of enfore, be precisely assessed.
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grafted human T cells. Such reactivity against mouse T cells In general, the evaluation of the occurrence and seventy was indicated indirectly when we found that the number of of GVHD, in animal models and in humans, is not straightresidual murine T lymphocytes was markedly reduced in forward because many of its symptoms are also compatible recipients of 80 x IO6 human cells, compared with recipients with infectious diseases. It is therefore not surprising that of 10 x IO6 cells. However, GVHD was not as aggressive there is some disagreement regarding possible GVHD-assoas in allogeneic models and the overall survival, during the ciated mortality after transplantation of human PBLs in the first 3 months posttransplant, of human --* mice chimera was SCID similar difficulties in the evaluation of about 50% to 60%, similar to that found in control mice GVHD were also encountered in our study. Within 3 weeks identically condition& and radioprotected with SCID bone marrow but not receiving human PBLs. Perhaps most significant, in this context, is our finding that the engraftment of human PBLs in BALB/c mice, at doses as high as 80 X lo6 cells, did not Iead to EBV lymphoma, as reported for SCID m i~e . ' .~.~' ,~~~ This is beneficial when using PBLs or tissues from EBV seropositive normal donors or patients. There could be several explanations for the absence of endogenous EBV lymphoma in lethally irradiated human + mice chimera. It may reflect engraftment of T cells capable of specific immune response against EBV-transformed cells, which has been shown to operate in EBV seropositive humans. A second possibility is that a murine T-cell subpopulation, remaining after TBI, is still capable of eliminating EBV-infected human B cells. The latter possibility is more likely as we found that the level of immune deficiency in the recipient mice was correlated with the incidence of lymphoma. Thus, the lethally irradiated BALB/c recipients did not have any incidence of lymphoma, whereas lethally irradiated BNX mice were more prone to develop this complication. Furthermore, the inci- dence in BNX recipients was still lower than that reported in the literature for the SCID mice. A detailed study, using lymphocytes from leukapheresis of a single EBV' donor, has indicated that the highest incidence of lymphoma developed in SCID mice, whereas a significantly lower incidence was found in BNX mice radioprotected with SCID bone marrow, and no lymphoma was detected in radioprotected BALBk recipients (unpublished results). Clearly, the xenoreactivity in the BALBIc recipients, which might have controlled EBV-infected cells in the PBL transplant, may also be capable of rejecting the entire xenograft of human PBLs. However, because of quantitative differences, it is likely that we have empirically reached a situation in which the residual host-type mouse T cells may still be able to control the very minute number of EBV-infected B cells, but fail to prevent LUBIN ET AL engraftment of the massive number of transplanted normal PBLs.
Studies in allogeneic chimera suggested that antiviral cytotoxic T lymphocytes, which are restricted to MHC class I, exhibit poor activity in such chimera"; this was explained by inadequate antigen presentation after bone marrow transplantation from MHC-mismatched donors. The disparity is even more drastic in human --t mouse chimera and it would be quite surprising if the control of human EBV' B cells were found to be mediated by mouse cytotoxic T lymphocytes. Studies to characterize the cells involved in EBV resistance are in progress.
The above considerations regarding xenoreactivity of mouse antihuman EBV-infected cells, based on data obtained in different immunodeficient recipients, are also relevant in addressing the role of T-cell and non-T-cell-mediated mechanisms of xenograft rejection in lethally irradiated mice.
(1) The role of residual mouse T cells, remaining after the supra-lethal conditioning, has been strongly indicated by For personal use only. on October 26, 2017. by guest www.bloodjournal.org From nude BALB/c mice as opposed to normal BAL,B/c mice. The residual murine T cells may proliferate and increase in number in response to human antigens. Alternatively, a second source of T cells could be provided by residual stem cells that can differentiate and develop in the mouse thymus to form, within a few weeks, a significant new pool of T lymphocytes. This possibility was confirmed by our experiments in which thymectomy before transplantation led to a significant reduction in the number of recumng mouse T cells and to improvement of human lymphocyte engraftment. Preliminary results suggest that, in the future, we may be able to achieve the same elimination of mouse T cells, as well as improvement of human PBL engraftment, by using antimouse CD4 and antimouse CD8 monoclonal antibodies in vivo.
(2) Our results with the BNX recipients (which are immunodeficient because of the absence of a thymus, natural killer (NK) cells, and some B-cell functions, including production of natural antibodies) demonstrate a marked degree of resistance to human PBL engraftment, even when using conditioning with 4 Gy TBI, as described by Kamel-Reid and Dick for engraftment of myeloid progenitor^.^' Only after using a lethal dose of TB1 did it become possible to achieve consistent engraftment, thus suggesting an alternative mechanism of xenograft rejection that may be mediated by non-T, non-NK cells. A candidate cell that could mediate such rejection may be the monocytelmacrophage, which was shown to be involved in rejection of tumors via a cell surface lectin." (3) Huppes et a13' suggested recently that human PBLs cannot be engrafted in lethally irradiated mice that possess natural antibodies, even after infusion of very large doses of cells. This conclusion was based on a short-term mortality assay that, according to the investigators, reflected acute GVHD. Marked mortality and engraftment were found, within the first 2 weeks posttransplant of human PBL, in strains of mice that were either deficient in natural antibodies or had been manipulated immediately after birth to have such a deficiency. Engraftment and subsequent acute GVHD were not found in lethally irradiated strains of mice that possessed natural antibodies. Our results now show that consistent engraftment, for periods much longer than 14 days and with much lower doses of human PBLs, can be achieved in recipients possessing natural antibodies. Two differences between the studies could account for this discrepancy: (a) we used a much more intensive conditioning; and (b) we used SCID bone marrow for radioprotection, whereas Huppes et aI3l used autologous bone marrow, which has normal lymphoid precursors and therefore can promptly reconstitute murine lymphocytes capable of rejecting the transplanted human PBLs. Our experiment, comparing T-cell-depleted BALB/c bone marrow with SCID bone marrow (Fig 4) , strongly supports the second possibility.
There are many similarities between the quality and the type of engraftment achieved in the SCID mouse and in the lethally irradiated normal BALB/c mice, which are converted into SCID-like mice by virtue of bone marrow transplantation from an SCID donor. However, in addition to the difference in the development of EBV lymphoma, another major difference is associated with the kinetics of homing of the engrafted cells to internal organs. Whereas in the SCID mouse, after IP infusion of human PBLs, the cells remain in the peritoneal cavity for more than 30 days before homing to spleen, liver, and l~n g s , '~ we found that such homing in the human -+ BALB/c chimera takes place within 24 hours of infusion. Consequently, the tempo of human Ig production, as well as the appearance of activated T cells, was very prompt. This rapid dissemination and activation should be taken into account when planning immunization schedules. Our preliminary experience with a few tested antigens suggests that it may be possible to successfully complete the immunization schedule within 1 month from the day of the PBL transplant and, therefore, the 2-to 3-month engraftment period attained in our model is sufficient for obtaining cell lines secreting human antibodies and it may also be adequate to afford antigen-specific human T-cell lines.
Tary-Lehmann and Saxon" have shown that human T cells, which are recovered from human -+ mouse chimera after transplantation into SCID mice, are anergic in vitro and can only be stimulated by exogenous IL-2. This was attributed in part to an inappropriate antigen-presentation by "nonprofessional" antigen-presenting cells. A detailed study of the functionality of the engrafted human cells in our model has been undertaken. Preliminary results indicate that the recovered human T cells exhibit responses to OKT3 in the absence of IL-2 and that the mice are capable of strong antibody responses to tetanus and weak primary response to keyhole lymphoid hemagglutinin (unpublished results).
The elucidation of the functional capabilities of the engrafted human cells is of importance for the establishment of different potential applications, including production of human monoclonal antibodies against self and nonself antigens, and development of a model for the evaluation of new vaccines against infectious diseases and tumor cells. In this context, we demonstrated that OUT approach permits the transplantation of human cells into transgenic mice bearing human HLA determinants (Table 2) . Antigen presentation, and thereby the immune responsiveness of partially matched engrafted human lymphocytes, may be more effective in such recipients. A similar improvement may also be achieved by using other rodents, in which hematopoietic cytokines are more cross-reactive with human cytokines. Preliminary results suggest that the murine SCID bone marrow is capable of radioprotecting lethally irradiated rats and that such SCIDlike rats can also accept human PBLs. Therefore, our approach may not only provide means for the transplantation of human PBLs in different strains of mice, but it could also afford a general approach for the production of human chimerism in any other species that can be radioprotected by the bone marrow of the SCID mouse. For personal use only. on October 26, 2017. by guest www.bloodjournal.org From
